RxDoctor Payments Data

Jinal Shah, MD

Neurology · Sugarland, TXNPI 1225224157

Payments from drug & device makers

$19,934in general payments, 2019–2025

Across 1,025 payments — averaging $19.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Novartis$1K
  • UCB, Inc.$1K
  • Genentech, Inc.$1K
  • Pfizer$1K
  • Teva Pharmaceuticals USA, Inc.$997
  • plus $10K from 54 others

What the payments were for

  • Consulting fees$1,3607%
  • Speaking & faculty fees$4752%
  • Food & beverage$18,06691%
  • Education$340%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)225$3,700
Novartis100$1,458
UCB, Inc.54$1,310
Genentech, Inc.1$1,060
Pfizer73$1,003
Teva Pharmaceuticals USA, Inc.69$997
Amgen(2 entities)36$841
SK Life Science, Inc.34$773
Biogen25$771
Acadia Pharmaceuticals Inc31$599
Acorda Therapeutics, Inc22$509
EMD Serono, Inc.26$499
Abbott28$475
Genentech USA, Inc.28$469
Neurocrine Biosciences, Inc.19$436
Lilly USA, LLC25$422
AstraZeneca17$398
Amneal Pharmaceuticals LLC20$292
Takeda Pharmaceuticals U.S.A., Inc.11$281
Lundbeck LLC12$274
Argenx US, Inc.10$273
Sanofi13$265
Eisai Inc.9$204
Biohaven Pharmaceutical Holding Company Ltd.16$199
Biohaven Pharmaceuticals, Inc.15$174
Merz Pharmaceuticals, LLC7$156
Grifols USA, LLC7$153
Arbor Pharmaceuticals, Inc.8$127
Hospira, Inc.6$127
Boston Scientific3$119
Neurelis, Inc.5$117
Medtronic(3 entities)5$97
Si-bone, Inc.1$93
Catalyst Pharmaceuticals, Inc.3$81
E.r. Squibb & Sons, L.L.C.4$74
TG Therapeutics, Inc.3$62
Assertio Therapeutics, Inc.3$56
Aquestive Therapeutics, Inc.3$56
Greenwich Biosciences, Inc.3$54
Avadel CNS Pharmaceuticals, LLC2$54
Livanova USA, Inc.3$51
Sunovion Pharmaceuticals Inc.3$51
Kyowa Kirin, Inc.2$50
Vanda Pharmaceuticals Inc.3$49
Jazz Pharmaceuticals Inc.2$49
Johnson & Johnson(2 entities)2$48
Bristol Myers Squibb2$47
Upsher-smith Laboratories LLC3$46
Tanabe Pharma America, Inc.3$43
Merz North America, Inc.2$43
GE HealthCare2$41
Teleflex LLC1$39
Azurity Pharmaceuticals, Inc.2$36
Bausch Health US, LLC2$34
Elutia, Inc.1$23
Microtransponder, Inc.1$22
Xeris Pharmaceuticals, Inc.1$22
Integra Lifesciences Corporation1$22
Vertical Pharmaceuticals, LLC1$20
Supernus Pharmaceuticals, Inc.1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,934 in reported general payments places this provider in the 75th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$156,295
Medicare patients
394
Services billed
6,208

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RystiggoRozanolixizumab-Noli14$482,062
Kesimpta PenOfatumumab14$138,303
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5011$77,201
OctagamImmun Globg(Igg)/Malt/Iga Ov5016$68,847
VimpatLacosamide34$25,277
Aimovig AutoinjectorErenumab-Aooe22$24,634
Glatiramer Acetate13$19,925
Nurtec OdtRimegepant Sulfate11$16,950
BriviactBrivaracetam12$16,805
Memantine Hcl370$13,344
Emgality PenGalcanezumab-Gnlm12$8,396
Lacosamide29$7,645
Gabapentin330$4,782
Donepezil Hcl404$3,488
Pregabalin182$3,236

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Rystiggo, Vimpat, Briviact$1,310$524,14460 claims
PfizerOctagam, Nurtec Odt$1,003$85,79627 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil$292$3,53970 claims
Upsher-smith Laboratories LLCTopiramate$46$65471 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,246 neurology providers in Texas.

Other neurology in Sugarland

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →